AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
_6ff029a61766633234293.png?format=webp&width=1186&height=250)
Biotech Stocks with High Momentum Scores
ByAinvest
Saturday, Sep 13, 2025 6:26 am ET1min read
Dianthus Therapeutics Inc. (DNTH) has seen a 90% surge in the past month due to positive Phase 2 trial results for its lead asset, claseprubart (DNTH103), in generalized myasthenia gravis. The stock's Momentum score has surged from 31.69 to 88.24 over the past 7 days. Korro Bio Inc. (KRRO) has soared in Benzinga’s Momentum rankings by 50.26 points, from 22.39 to 72.65, due to the company's recently secured Orphan Drug Designation for its lead RNA-editing therapy, KRRO-110. Centessa Pharmaceuticals PLC (CNTA) has seen a 48.75 point jump in its Momentum score, from 38.07 to 86.82, with a 42.85% spike over the past week alone.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet